CRIMINAL LAWAND PROCEDURE
120
alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-
methyl-2-piperidinyl)methyl, 2-(4-mor-
pholinyl)ethyl, or 1-(N-methyl-2-pyrro
lidinyl)methyl, 1-(N-methyl-3- mor-
pholinyl)methyl, or tetrahydropyranyl-
methyl group, whether or not further
substituted in the indole ring to any extent
and whether or not substituted in the phenyl
ring to any extent.
(8) Any compound, except bupropion or a
compound listed under a different sched-
ule, structurally derived from 2-amino-
propan-1-one by substitution at the
1-position with either phenyl, naphthyl,
or thiophene ring systems, whether or not
the compound is further modified:
(A) by substitution in the ring system
to any extent with alkyl, alkylenedioxy,
alkoxy, haloalkyl, hydroxyl, or halide
substituents, whether or not further
substituted in the ring system by one or
more other univalent substituents;
(B) by substitution at the 3-position
with an acyclic alkyl substituent;
(C) by substitution at the 2-amino
nitrogen atom with alkyl, dialkyl, ben-
zyl, or methoxybenzyl groups; or
(D) by inclusion of the 2-amino nitro-
gen atom in a cyclic structure.
(9) Any compound structurally derived
from 3-tetramethyl cyclopropanoylindole
with substitution at the nitrogen atom of the
indole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piper
idinyl)methyl, 2-(4-morpholinyl) ethyl, 1-
(N-methyl-2-pyrrolidinyl) methyl, 1-(N-
methyl- 3 -morpholinyl) methyl, or
tetrahydropyranylmethyl group, whether or
not further substituted in the indole ring to
any extent and whether or not substituted
in the tetramethylcyclopropyl ring to any
extent.
(10) Any compound containing a N-(1-
adamantyl)- 1H-indazole-3-carboxamide
structure with substitution at the nitrogen
atom of the indazole ring by an alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkyl-
methyl, cycloalkylethyl, 1-(N-methyl-2-
piperidinyl)methyl, or 2-(4-morph-olinyl)
ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, whether or
not further substituted at the nitrogen atom
of the carboxamide to any extent, whether
or not further substituted in the indazole
ring to any extent, and whether or not fur-
ther substituted on the adamantyl ring sys-
tem to any extent. An example of this
structural class includes AKB48.
(11) Any compound containing a N-(1-
adamantyl)- 1H-indole-3-carboxamide
structure with substitution at the nitrogen
atom of the indole ring by an alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkyl-
methyl, cycloalkylethyl, 1-(N-methyl-2-
piperidinyl)methyl,
or
2-(4-mor-
pholinyl)ethyl, 1-(N-methyl-2-pyrro-
lidinyl)methyl,1-(N-methyl-3-morpholinyl)
methyl, or tetrahydropyranylmethyl group,
whether or not further substituted at the
nitrogen atom of the carboxamide to any
extent, whether or not further substituted
in the indole ring to any extent, and
whether or not further substituted on the
adamantyl ring system to any extent. An
example of this structural class includes
STS-135.
(12) Any compound containing a 3-(1-
adamantoyl)indole structure with substi-
tution at the nitrogen atom of the indole
ring by an alkyl, haloalkyl, cyanoalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2- piperidinyl)methyl, or 2-
(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3-mor-
pholinyl)methyl, or tetrahydropyranyl-
methyl group, whether or not further
substituted on the adamantyl ring system
to any extent.An example of this structural
class includes AM-1248.
(13) Any compound determined to be a
synthetic drug by rule adopted under IC 25-
26-13-4.1.
35-31.5-2-321.5. “Synthetic drug lookalike
substance” defined.
